Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

argenx

Rare disease drugmaker · based in Zwijnaarde, Belgium · founded 2008 · ticker ARGX · argenx.com

argenx works on 11 rare diseases we track, including Chronic Inflammatory Demyelinating Polyneuropathy, Dermatomyositis and 9 more. It has 30 active clinical trials, and 20 are looking for volunteers now. It also has 2 FDA-approved rare disease drugs.

argenx is a global immunology company focused on FcRn-blocking antibody therapies for rare autoimmune diseases. Vyvgart (efgartigimod alfa), given by IV infusion, was approved in December 2021 for adults with generalized myasthenia gravis who test positive for AChR antibodies.

argenx pipeline

Each row lists the diseases argenx is studying at that stage, from the ones closest to approval down to the earliest work.

Approved
Drugs the FDA has approved.
Phase 3
Large studies, usually the last step before a company asks the FDA for approval.

Myasthenia Gravis 5 trials recruiting · Immune Thrombocytopenia 3 trials recruiting · Chronic Inflammatory Demyelinating Polyneuropathy 2 trials recruiting · Graves’ Disease 2 trials recruiting · Sjögren's Syndrome

Phase 2
Mid-size studies that check whether a drug works and at what dose.
Phase 1
First studies in people, mostly checking safety.

Leukemia, Myeloid, Acute

After approval
Studies that follow people already taking an approved drug.

Myasthenia Gravis 2 trials recruiting

Other studies
Studies with no phase listed, such as registries and natural history studies.

argenx clinical trials

These are argenx trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.

20 trials looking for volunteers now

Looking for volunteersPhase 3Recently updatedNCT07091630

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Tests Empasiprubart IV, Placebo IV

For Chronic Inflammatory Demyelinating Polyneuropathy, CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

Ages 18 Years+94 locations
View full study
Looking for volunteersPhase 2Recently updatedNCT07673627

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Tests Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS

For AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis and gMG

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG). The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward2

Ages 18 Years+14 locations
View full study
Looking for volunteersRecently updatedNCT07264426

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Tests Efgartigimod PH20 SC

For Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP and CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Ages 18 Years+23 locations
View full study
Looking for volunteersPhase 3Recently updatedNCT07596849

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

Tests efgartigimod PH20 SC, Placebo PH20 SC

For Graves Disease

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Ages 18 Years+51 locations
View full study
Looking for volunteersPhase 3Recently updatedNCT06920004

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Tests empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo

For Chronic Inflammatory Demyelinating Polyneuropathy, CIDP and CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Ages 18 Years+107 locations
View full study
Looking for volunteersPhase 3Recently updatedNCT07570316

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Tests Efgartigimod PH20 SC, Placebo PH20 SC

For Graves' Disease and Graves Disease

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Ages 18 Years+35 locations
View full study
Looking for volunteersPhase 2Recently updatedNCT07773727

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

Tests ARGX-121, Placebo

For Immunoglobulin A Nephropathy (IgAN)

The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN. While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise. The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.

Ages 18 Years+11 locations
View full study
Looking for volunteersRecently updatedNCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Tests Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS

For Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis and Generalized Myasthenia Gravis (gMG)

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Ages 18 Years+37 locations
View full study
Ask about argenx's trials
Answers with sources, in plain English
Start withor ask
Follow a condition argenx is studying

Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only argenx. Unsubscribe anytime.

You'll get, for Chronic Inflammatory Demyelinating Polyneuropathy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

FDA-approved drugs from argenx

From the openFDA database. Tap a drug for side effects, dosing and help paying.

Vyvgart efgartigimod alfa

For Myasthenia Gravis. Approved Dec 17, 2021. Taken by intravenous route.

VYVGART Hytrulo efgartigimod alfa and hyaluronidase (human recombinant)

For Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy. Approved Jun 20, 2023. Taken by subcutaneous route.

More about argenx

Vyvgart Hytrulo, given as an injection under the skin, was approved for the same group in June 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in June 2024, and a prefilled syringe for self-injection followed in April 2025.

On May 8, 2026, the FDA expanded both labels to all adults with generalized myasthenia gravis, including people who test positive for MuSK or LRP4 antibodies and people who test negative for AChR, MuSK and LRP4 antibodies. In August 2026, argenx and Zai Lab reported that the Phase 3 ALKIVIA trial met its main goal in autoimmune myositis.

Registrational trials continue in immune thrombocytopenia and Graves' disease, and empasiprubart is in registrational trials for multifocal motor neuropathy and CIDP. On October 8, 2026, argenx stopped its Phase 3 UNITY trial in Sjögren's disease after an independent data monitoring committee found it was unlikely to meet its main goal. argenx stopped its pemphigus program after the Phase 3 ADDRESS trial missed its main goal in December 2023.

Where argenx trials take place

The trials above run at 1,665 study sites in 59 countries. Tap a country to see its states, cities and hospitals.

United States
323▼
Germany
132▼
Italy
117▼
Poland
109▼
China
108▼
Japan
98▼
Spain
78▼
France
52▼
United Kingdom
49▼
Georgia
48▼
Greece
31▼
Bulgaria
29▼

Rare diseases argenx works on

Each disease page lists every open trial, not only argenx's, plus approved treatments.

Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder affecting the peripheral nerves, causing progressive weakness and impaired function in the legs and arms.

How common: About 2.8 per 100,000 people in a 2019 pooled analysis of 9 studies (Broers et al., Neuroepidemiology); NORD estimates 5 to 7 per 100,000, and NIH's GARD estimates about 50,000 people in the U.S

Dermatomyositis

Dermatomyositis is a rare autoimmune inflammatory disease causing muscle weakness and distinctive skin rashes, particularly over joints.

How common: About 9.6 new cases per million people a year, according to NORD; juvenile-onset incidence about 0.4 cases per 100,000 children

Epidermolysis Bullosa

Epidermolysis bullosa is a group of rare genetic blistering disorders caused by mutations affecting proteins anchoring the epidermis to the dermis.

How common: 1 in 50,000 births; approximately 25,000-30,000 Americans affected

Graves’ Disease

Graves' disease is the most common cause of hyperthyroidism, an autoimmune condition where antibodies stimulate the thyroid gland to produce excessive thyroid hormone.

How common: Affects about 1 in 200 people; most common in women ages 30-50

Guillain-Barré Syndrome

Guillain-Barré syndrome is a rare autoimmune neurological disorder in which the body's immune system attacks the peripheral nerves, causing rapidly progressive muscle weakness that typically starts...

How common: 1 in 60,000 people per year in the U.S. (3,000 to 6,000 new cases annually)

IgA Nephropathy

IgA nephropathy is the most common primary glomerulonephritis worldwide, caused by abnormal IgA1 antibodies depositing in the kidney's mesangium, activating complement pathways and triggering...

How common: About 2 new cases per 100,000 people each year in the U.S., and an estimated 199,000 to 208,000 Americans were living with IgA nephropathy in 2021 (Otsuka-funded study, Clinical Nephrology, 2025)

Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a rare autoimmune disorder in which the immune system destroys platelets, the blood cells that stop bleeding, and slows their production.

How common: Estimated 9 to 20 per 100,000 people; children often have a temporary form that resolves within months

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue.

How common: 1 in 5,000 people

Sjögren's Syndrome

Sjögren's syndrome is a chronic autoimmune disorder in which the immune system attacks the moisture-producing exocrine glands, primarily the salivary and lacrimal (tear) glands.

How common: Estimated 1 to 4 million Americans (including undiagnosed); approximately 1 in 1,000 adults based on physician-diagnosed prevalence

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing progressive muscle weakness and atrophy.

How common: About 1 in 10,000 births; about 1 in 50 people of European or Asian ancestry are carriers of 1 copy of the gene change

Systemic Sclerosis

Systemic sclerosis (scleroderma) is a rare autoimmune disease in which the immune system triggers scarring (fibrosis) of the skin and internal organs while also damaging small blood vessels.

How common: About 276 per million U.S. adults in a large Detroit-area study; about 19 new cases per million adults each year

Where to get support

Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. argenx's own site is argenx.com, and our help paying for treatment page lists drugmaker programs and charity funds.

Questions about argenx